Literature DB >> 32055212

Effect of IGFBP2 Overexpression on the Expression of Fatty Acid Synthesis Genes in Primary Cultured Chicken Hepatocytes.

Yanshuang Mu1, Yuhang Sun1, Li Leng1, Zhiping Cao1, Yumao Li1, Hui Li1, Yuxiang Wang1.   

Abstract

The effects of insulin-like growth factor binding protein 2 (IGFBP2) on the expression of fatty acid synthesis regulators and triglyceride production were investigated in primary cultured chicken hepatocytes. The full-length chicken IGFBP2 coding region was synthesized by overlap extension PCR and cloned into the pcDNA3.1 vector. An in situ digestion method was used to prepare the chicken hepatocytes. Primary chicken hepatocytes were maintained in monolayer culture. Real-time PCR was used to detect changes in the expression of IGFBP2, PPARG, IGF1, IGF1R, APOAI, and LFABP, after the overexpression of IGFBP2 in chicken hepatocytes. Triglyceride production and glucose content were also evaluated using triglyceride and glucose analysis methods. The expression level of IGFBP2 increased after transfection of the IGFBP2-containing vector. The expression levels of PPARG, IGF1, and IGF1R also increased in cultured chicken hepatocytes after the overexpression of IGFBP2, whereas the expression of LFABP and APOAI decreased. Triglyceride production in primary cultured chicken hepatocytes increased after the overexpression of IGFBP2. These results suggest that IGFBP2 is involved in lipogenesis, increasing both the expression of fatty acid synthesis regulators, and triglyceride production in primary cultured chicken hepatocytes. 2019, Japan Poultry Science Association.

Entities:  

Keywords:  chicken; hepatocyte; insulin-like growth factor binding protein 2; triglyceride

Year:  2019        PMID: 32055212      PMCID: PMC7005387          DOI: 10.2141/jpsa.0180114

Source DB:  PubMed          Journal:  J Poult Sci        ISSN: 1346-7395            Impact factor:   1.425


Introduction

In birds, the liver is the main site of de novo fatty acid synthesis, and accounts for more than 70% of all lipid production (Griffin ). In liver, synthesized fatty acid are incorporated into triglycerides, which are the major components of lipoproteins (Hillgartner ). Adipose tissues only serves as a lipid storage site in avians (Saadoun and Leclercq, 1987). Therefore, 60–80% of the triglyceride storage in avian adipose tissues is dependent upon the availability of plasma lipid substrate originating from hepatic lipogenesis (Griffin ). Understanding lipid metabolic pathways in the liver is crucial for identifying the genes responsible for fat deposition in chickens. The proper regulation of gene networks in the liver is integral to the maintenance of fatty acid synthesis. Several factors have been identified as key regulators of lipid and lipoprotein metabolism in the liver, including peroxisome proliferator-activated receptors (PPARs), insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1R), liver fatty acid binding protein (LFABP), and apolipoprotein AI (APOAI). Peroxisome proliferator-activated receptor gamma (PPARG) is a member of the nuclear hormone receptor family, and functions in the liver as a transcription factor that regulates fatty acid catabolism and lipid export (Wahli and Michalik, 2012). IGF1, IGF1R, and their signaling pathways play critical roles in stimulating lipogenesis (Accili ). APOAI is the main structural component of high-density lipoproteins and a lecithin-cholesterol acetyltransferase activator, and thus plays roles in lipoprotein assembly, lipid transport, and lipid metabolism, by mediating the interactions of these proteins with receptors, enzymes, and lipid transport proteins (Rosenson ). LFABP delivers the fatty acid substrates required to synthesize triglycerides, and prevents the detergent effects of fatty acids in cells (Storch and McDermott, 2009). These genes profoundly affect various overlapping aspects of fatty acid synthesis, and participate in significant cross-talk to coordinate lipid homeostasis. IGF binding protein 2 (IGFBP2) is a secreted protein that binds IGFI and IGFII with high affinity (Rajaram ; Fuller ). IGFBP2 secreted by chicken preadipocytes can affect IGF activity in adipose tissues (Clemmons ; Butterwith, 1994). In pigs, IGFBP2 regulates the proliferation and differentiation of preadipocytes, which is indirectly mediated by IGF or transforming growth factor β (TGFβ) signals (Richardson ; Gonzalez-Fernandez ). IGFBP2 also interacts with many different ligands, independent of its binding to IGF (Wang ; Chua ). In previous studies, IGFBP2 was shown to interact directly with the gene encoding integrin α5 (ITGB1), and also to independently activate the EGFR/STAT3 signaling pathway (Wang ; Chua ). Our previous studies and other studies have suggested that the IGFBP2 gene is a candidate locus, or linked to a major gene that affects chicken fatness, growth, and carcass traits (Lei ; Li ; Leng ; Gholami ). However, the molecular mechanisms underlying the regulation of triglyceride synthesis by IGFBP2 remain unclear. Based on the available information, this study was undertaken to evaluate the effects of IGFBP2 on the expression of fatty acid synthesis regulators and triglycerides in cultured chicken hepatocytes.

Materials and Methods

Animals

The broilers (18–22 days old) used in this study were derived from Northeast Agricultural University broiler lines divergently selected for high and low abdominal fat content (NEAUHLF) (Li ; Leng ). Broilers from low abdominal fat content lines were selected for this study. In each experiment, three broilers were used for hepatocyte culture. All the chickens were kept under the same environmental conditions and had free access to feed and water. All animal experiments performed in this study were approved by the Institutional Animal Care and Use Committee of Northeast Agriculture University (IACUC-02-005).

Test Reagents

All chemicals and reagents were supplied by Sigma–Aldrich (St. Louis, MO, USA), unless otherwise indicated.

Cloning the Chicken IGFBP2 Coding Sequence (CDS)

The chicken IGFBP2 CDS is 936 bp long, with a high-GC-content region. To isolate the CDS of chicken IGFBP2, we used overlap extension PCR. First, a 421-bp region of the IGFBP2 cDNA with a high GC content was synthesized as 12 fragments (Table 1), and the synthesized oligonucleotides were diluted separately to 50 µmol/l. In the first-round PCR, 50 µl of the reaction mixture contained 2 µl each of 10 pmol/µl primers BP2-OF6 and BP2-OR6, 0.4 µl of 5U/µl Pyrobest™ DNA Polymerase (Takara, Shiga, Japan), 5 µl of 10×Pyrobest Buffer, 4 µl of 2 mmol/l dNTPs, and 36.6 µl of H2O. The PCR cycling conditions were 94 C for 5 min, followed by 20 cycles of 94°C for 40 s, 55°C for 40 s, and 72°C for 40 s, followed by 72°C for 10 min. In the second-round PCR, the template was the product of the first-round PCR, and the primers were BP2-OF5 and BP2-OR5. The second-round PCR cycling conditions were the same as those for the first-round PCR. In subsequent PCRs, the last PCR product was used as the next PCR template, and the primer pairs BP2-OF4 and BP2-OR4, BP2-OF3 and BP2-OR3, BP2-OF2 and BP2-OR2, and BP2-OF1 and BP2-OR1 were used consecutively. The PCR cycling conditions in these rounds were the same as those in the first-round PCR. Thus, the 421-bp sequence of the IGFBP2 CDS was obtained after six rounds of PCR.
Table 1.

Oligonucleotide primer sequences used to amplify IGFBP2

NoNameSequence (5′ to 3′)
1BP2-OF1ATGGCGCTCGGCGGGGTCGGTCGCGGCGGCGCGGCGCGGG CCGCTTGGCC
2BP2-OF2GCGGCGCGGGCCGCTTGGCCGCGGTTGCTGCTGGCGGCGTTGGCGCCGGC GCTGGCGC
3BP2-OF3GT TGGCGCCGGC GCTGGCGCTG GCGGGGCCGG CGCTGCCCGA GGTGCTGTTC CGC
4BP2-OF4TGCCCGA GGTGCTGTTC CGCTGCCCGC CCTGCACGGC GGAACGCCTG GCC
5BP2-OF5GCACGGC GGAACGCCTG GCCGCTTGCT CCCCGGCCGC CCGGCCGCCC TGC
6BP2-OF6CGGCCGC CCGGCCGCCC TGCCCCGAGC TGGTGCGGGA ACCGGGCTGC GGCTGCTGTC C
7BP2-OR1GACCGGTCAT CACCGTTGTC TGCGGGGGGC TCGGTGCTGG CTCCGTACTC
8BP2-OR2TCGGTGCTGG CTCCGTACTC GTCCGTGTCG GGGGGGCGGG CGCAGGTGCC CTGTCCCT
9BP2-OR3GG CGCAGGTGCC CTGTCCCTGG ACCAGGGCTT GGGGGGGCAG CTCGGCTCCG GGG
10BP2-OR4GGGGCAG CTCGGCTCCG GGGTCGGGGT AGCAGCGCAA ACCGGCGGCG CAG
11BP2-OR5AGCGCAA ACCGGCGGCG CAGCGCGGGG TGTACACGCC GCACGCCTCG TCC
12BP2-OR6ACACGCC GCACGCCTCG TCCTCCAGGC GGGCGCACAC CGGACAGCAG CCGCAGCCCG G
The remaining 536-bp CDS fragment of IGFBP2 with a normal GC content was generated with routine reverse transcription PCR. The PCR mixture (50 µl) contained 2 µl of 2 ng/µl cDNA from chicken adipose tissue, 1 µl each of 10 pmol/µl primers IGFBP-2E-F and IGFBP-2E-R (Table 2), 0.4 µl of 5U/µl Pyrobest™ DNA Polymerase, 5 µl of 10×Pyrobest Buffer, 4 µl of 2 mmol/l dNTPs, and 36.6 µl of H2O. The cycling conditions for the PCR was 94°C for 5 min, followed by 33 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, followed by 72°C for 10 min.
Table 2.

Sequences of primers used for real-time PCR

NoGeneTypePrimers NamePrimer Sequence (5′ to 3′)Amplicon (bp)
1IGFBP2CloneIGFBP2E-FGACAACGGTGATGACCGGTC536
IGFBP2E-RAGCAAGCAGGACCACATCC
2IGFBP2CloneIGFBP2EcoRI-FGAGAATTCATGGCGCTCGGCGGGGTCGG936
IGFBP2XhoI-RCGCTCGCGGGACCACATCCATCTACTGGC
3PPARγExpressionPPARγ-FGTGCAATCAAAATGGAGCC170
PPARγ-RCTTACAACCTTCACATGCAT
4IGF1ExpressionIGF1-FTTCTTCTACCTGGCCTGTG147
IGF1-RCATACCCTGTAGGCTTACTG
5IGF1RExpressionIGF1R-FTTGGCTAATGGCTACTTTG177
IGF1R-RGTGCGTCATATTATCTTTCG
6LFABPExpressionLFABP-FTCACTGGAAAGTACGAGC390
LFABP-RGCATGCAGGGTCTCTAGATT
7ApoAIExpressionApoAI-FGCA TTC GGG ATA TGG133
ApoAI-RCTC AGC GTG TCC AGG TTG T
8IGFBP2ExpressionIGFBP2-FTGC CGG ATG AGC GAG GTC117
IGFBP2-RCCA TTC ACC GAC ATC TTG C
918SExpression18S-FTAGATAACCTCGAGCCGATCGCA321
18S-RGACTTGCCCTCCAATGGATCCTC
Finally, the entire 936 bp CDS of IGFBP2 was obtained by fusing the 421 bp and 536 bp cDNA fragments by overlap extension PCR. The PCR mixture (50 µl) contained 2 µl of the 421 bp fragment and 2 µl of the 536-bp fragment, 0.4 µl of Pyrobest™ DNA Polymerase, 5 µl of 10×Pyrobest Buffer, 4 µl of 2 mmol/l dNTPs, and 36.6 µl of H2O. The cycling conditions for the PCR were 94 C for 5 min, followed by 33 cycles of 94°C for 45 s, 60°C for 45 s, and 72°C for 45 s, followed by 72°C for 10 min. The product was stored at −20°C.

Construction of Chicken IGFBP2-expressing Plasmid

EcoRI and XhoI (Takara) restriction endonuclease sites were introduced into the 936 bp chicken IGFBP2 CDS by PCR. The PCR mixture (50 µl) contained 2 µl of DNA encoding the 936 bp CDS of the chicken IGFBP2 gene, 1 µl each of 10 pmol/µl primers IGFBP-2EcoRI-F and IGFBP-2XhoI-R (Table 2), 0.4 µl of 5 U/µl Pyrobest™ DNA Polymerase, 5 µl of 10×Pyrobest Buffer, 4 µl of 2 mmol/l dNTPs, and 36.6 µl of H2O. The cycling conditions for the PCR were 94°C for 5 min, followed by 33 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, followed by 72°C for 10 min. The IGFBP2 CDS and pcDNA3.1+ vector (Invitrogen, Carlsbad, CA, USA) were both digested with EcoRI and XhoI. The pcDNA3.1–IGFBP2 recombinant plasmid was obtained by ligating the prepared chicken IGFBP2 CDS and the pcDNA3.1 vector.

Chicken Hepatocyte Culture and Transfection

Chicken hepatocytes were prepared and maintained in a monolayer culture, as described previously (Fujii ). Broiler chickens were starved for 3 h and anesthetized with ether. Their livers were perfused in situ with calcium/magnesium-free Hanks' balanced salt solution (pH 7.5) for 20 min, followed by perfusion with Hanks' balanced salt solution (pH 7.5) containing 0.05% collagenase IV, for approximately 10–15 min at 37°C. The hepatocytes were released from the digested livers and suspended in 80 ml of precooled (4°C) serum-free Williams' E medium (Invitrogen) and filtered through nylon mesh (150 µm pores). The hepatocytes were then incubated for 30 min at 37°C and filtered through nylon mesh (75 µm pores) to remove any aggregated hepatocytes. The hepatocytes were washed three times with serum-free Williams' E medium, with centrifugation at 300×g for 3 min. Hepatocytes with > 90% viability, verified by Trypan Blue exclusion test, were plated (5.0×105 cells/60 mm collagen-coated dish) in incubation medium (Williams' E medium) containing 0.5 µg/ml insulin, 5 mg/l transferrin, 3 g/l glutamate amine, 10−7 mol/l dexamethasone, 100 U/ml streptomycin, 100 U/ml penicillin, and 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 atmosphere. After incubation for 4 h, the medium was replaced with fresh incubation medium. The monolayer cultures of hepatocytes were then used in experiments. The incubation medium was changed every 24 h. To determine the efficacy of IGFBP2 overexpression, chicken hepatocytes transfected with pcDNA3.1 were used as controls, and untransfected hepatocytes were used as blank controls. To transfect hepatocytes with the pcDNA3.1–IGFBP2 recombinant plasmid, 2 µg of the plasmid was diluted in 250 µl of serum-free Williams' E medium without antibiotics, mixed gently, and incubated at room temperature for 5 min. Lipofectamine™ 2000 liposomes (10 µl; Invitrogen) were added to 240 µl of serum-free Williams' E medium without antibiotics, mixed gently, and incubated at room temperature for 5 min. The diluted Lipofectamine™ 2000 and pcDNA3.1–IGFBP2 plasmid were then gently mixed together and incubated at room temperature for 15 min to form liposome complexes. The liposome complexes were added to hepatocyte culture dishes, supplemented with incubation medium (Williams' E medium) containing 0.5 µg/ml insulin, 5 mg/l transferrin, 3 g/l glutamate amine, 10−7 mol/l dexamethasone, and 10% FBS without antibiotics, and incubated at 37°C in a 5% CO2 atmosphere. After incubation for 6 h, the culture medium was changed to the incubation medium containing antibiotics.

Total RNA Extraction, cDNA Synthesis, and Quantitative Real-time PCR Analysis

To analyze gene expression, the chicken hepatocytes were harvested with 0.25% trypsin–0.04% EDTA digestion solution, and the RNA was extracted with a PureLink™ Microto-Midi Total RNA Purification Kit with DNase I treatment (Invitrogen). cDNA was synthesized with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Gene expression was detected with SYBR® Premix Ex Taq™ (Perfect Real Time) (Takara) in 50 µl real-time reactions using the oligonucleotide primers shown in Table 2. All transcript levels were normalized to the corresponding level of 18S rRNA. Quantitative real-time PCR was performed with the ABI 7500 Real-Time PCR System. The 2™ΔΔCt method was used for relative quantification. To determine the efficacy of IGFBP2 overexpression, chicken hepatocytes transfected with pcDNA3.1 were used as controls, and untransfected hepatocytes were used as blank controls. Three culture cells were made from three individual broilers, and real-time PCR was done three times per sample.

Total Protein Determination

The cultured hepatocytes were digested with 0.25% trypsin and suspended in phosphate-buffered saline (PBS). They were washed three times with PBS, and lysed with repeated freeze-thaw cycles. Total protein was determined with the BCA Protein Assay Kit (Beyotime, Beijing, China). Three culture cells were made from three individual broilers, and total protein determination was performed three times per sample.

Glucose Determination

The cultured hepatocytes were digested with 0.25% trypsin and suspended in PBS. They were washed three times with warm PBS to remove any extracellular glucose, and adjusted to 106 cells/ml with PBS. The hepatocytes were homogenized in a glass homogenizer for 1 min. The glucose concentration was determined with a Total Carbohydrate Assay Kit (Sigma), and results were normalized to cellular protein concentration. Three culture cells were made from three individual broilers, and glucose determination was done three times per sample.

Triglyceride Determination

The cultured hepatocytes were digested with 0.25% trypsin and suspended in PBS. They were washed three times with PBS, adjusted to 106 cells/ml with PBS, and homogenized in a glass homogenizer for 1 min. The triglyceride concentration was determined with an Adipogenesis Kit (Sigma), and the results normalized to cellular protein concentration. Three culture cells were made from three individual broilers, and triglyceride determination was done three times per sample.

Statistical Analysis

Experimental data are expressed as means±SEM. All statistical analyses were performed with SPSS 19 software (Somers, NY, USA). One-way ANOVA with Student's t test was used to evaluate statistical significance between the different treatment groups. P<0.05 indicates significant difference.

Results

Primary Culture of Chicken Hepatocytes

At 1 h after inoculation, the chicken hepatocytes began to exhibit adherent growth. After 4 h in culture, 90% of the hepatocytes displayed adherent growth. After 24 h, the hepatocytes appeared as typical epithelial-like polygons, and the cell bodies had become flat and thin. After 3 days in culture, the hepatocyte cell junctions had become more compact, and the cells were flattened, stretched, and tightly adherent to the bottom surface of the culture dish (Fig. 1).
Fig. 1.

Primary culture of chicken hepatocytes. (A) Chicken hepatocyte morphology was observed by microscopy at 400-fold magnification. (B) Chicken hepatocyte morphology was observed at 1000-fold magnification.

Primary culture of chicken hepatocytes. (A) Chicken hepatocyte morphology was observed by microscopy at 400-fold magnification. (B) Chicken hepatocyte morphology was observed at 1000-fold magnification.

Cloning Chicken IGFBP2 CDS and Construction of Chicken IGFBP2 Expression Vector

The complete chicken IGFBP2 CDS was cloned by overlap extension PCR (Fig. 2A). The prepared chicken IGFBP2 CDS was ligated into the pcDNA3.1 eukaryotic expression vector, generating the pcDNA3. 1–IGFBP2 recombinant plasmid (Fig. 2B). The recombinant plasmid was digested with EcoRI and XhoI, yielding two fragments: the 5.5 kb pcDNA3.1 vector fragment, and the 936 bp chicken IGFBP2 CDS fragment (Fig. 2C).
Fig. 2.

Cloned chicken (A) Cloning the chicken IGFBP2 CDS. Lane1: DNA Marker DL2000, lane2: first-round PCR product, lane3: second-round PCR product, lane4: third-round PCR product, lane5: fourth-round PCR product, lane6: fifth-round PCR product, lane7: sixth-round PCR product, lane8: 936 bp full length of IGFBP2 coding sequence, lane9: 536 bp coding sequence of IGFBP2. (B) Map of chicken IGFBP2 expression vector. (C) Recombinant plasmid pcDNA3.1–IGFBP2 was digested with EcoRI and XhoI.

Cloned chicken (A) Cloning the chicken IGFBP2 CDS. Lane1: DNA Marker DL2000, lane2: first-round PCR product, lane3: second-round PCR product, lane4: third-round PCR product, lane5: fourth-round PCR product, lane6: fifth-round PCR product, lane7: sixth-round PCR product, lane8: 936 bp full length of IGFBP2 coding sequence, lane9: 536 bp coding sequence of IGFBP2. (B) Map of chicken IGFBP2 expression vector. (C) Recombinant plasmid pcDNA3.1–IGFBP2 was digested with EcoRI and XhoI.

Overexpression of Chicken IGFBP2 in Hepatocytes

After the hepatocytes were transfected with the pcDNA 3.1–IGFBP2 eukaryotic expression vector, the expression of IGFBP2 was significantly higher than in the control group after 24, 48, and 72 h (P<0.05; Fig. 3).
Fig. 3.

Overexpression of IGFBP2 in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Overexpression of IGFBP2 in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Effect of IGFBP2 Overexpression on the Expression of PPARG, IGF1, and IGF1R

After the overexpression of IGFBP2 in hepatocytes, the expression of PPARG, IGFI, IGFIR genes were significantly higher in the transfected hepatocytes than in the control groups at 24 and 48 h (P<0.05; Fig. 4). At 72 h, the expression of PPARG, IGFI, and IGFIR genes in the hepatocytes in the transfected group did not differ significantly from that in control groups (Fig. 4).
Fig. 4.

Expression of the (A) Expression of the PPARG gene in chicken hepatocytes. (B) Expression of the IGFI gene in chicken hepatocytes. (C) Expression of the IGFIR gene in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Expression of the (A) Expression of the PPARG gene in chicken hepatocytes. (B) Expression of the IGFI gene in chicken hepatocytes. (C) Expression of the IGFIR gene in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Effect of IGFBP2 on the Expression of LFABP and APOAI

After the overexpression of IGFBP2 in hepatocytes, the expression of the LFABP gene was significantly lower in the transfected hepatocytes than in either control group at 24 h (P<0.05; Fig. 5A). At 48 and 72 h, the expression of the LFABP gene in the transfected hepatocytes did not differ significantly from that in the control groups (Fig. 5A).
Fig. 5.

Expression of (A) Expression of the LFABP gene in chicken hepatocytes. (B) Expression of the APOAI gene in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP-2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Expression of (A) Expression of the LFABP gene in chicken hepatocytes. (B) Expression of the APOAI gene in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP-2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different. After the hepatocytes were transfected with the IGFBP2 expression vector, expression of the APOAI gene was significantly lower in the transfected hepatocytes, and the control group, than in the blank group at 24 h. However, the expression of the APOAI gene in the transfected hepatocytes did not differ significantly from that in the control group at 24 h (Fig. 5B). At 48 and 72 h, the expression of APOAI in the transfected hepatocytes did not differ significantly from that in the control groups (Fig. 5B).

Effect of IGFBP2 Overexpression on Triglyceride and Glucose Contents of Chicken Hepatocytes

After the hepatocytes were transfected with the IGFBP2 expression vector, the triglyceride content was significantly higher in the hepatocytes than in either control group at 48 and 72 h (P<0.05; Fig. 6A). However, there was no significant difference between the treatment group and the control group at 24 h (Fig. 6A).
Fig. 6.

Triglyceride and glucose contents in chicken hepatocytes. (A) Triglyceride content in chicken hepatocytes. (B) Glucose content in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different.

Triglyceride and glucose contents in chicken hepatocytes. (A) Triglyceride content in chicken hepatocytes. (B) Glucose content in chicken hepatocytes. ‘IGFBP2’ indicates chicken hepatocytes transfected with the pcDNA3.1–IGFBP2 vector. ‘Control’ indicates chicken hepatocytes transfected with the pcDNA3.1 vector. ‘Blank’ indicates untransfected chicken hepatocytes. Statistical analysis was performed on IGFBP2 versus controls. * P<0.05, significantly different. After the hepatocytes were transfected with the IGFBP2 expression vector, the glucose content was significantly higher in the hepatocytes than in the control groups at 24 and 48 h (P<0.05; Fig. 6B). However, there was no significant difference between the treatment group and the control group at 72 h (Fig. 6B).

Discussion

IGFBP2 is a secreted protein that functions by interacting with circulating IGFs to modulate IGF-mediated signaling (Baxter, 2000). We previously mapped a QTL significantly influencing abdominal fat weight, and the percentage of abdominal fat of chicken, on chicken chromosome 7, and IGFBP2 is the only known gene located within this QTL region (Wang ). We further found that a single nucleotide polymorphism (SNP) in the 3′-UTR of chicken IGFBP2, is significantly associated with chicken abdominal fat weight and percentage of abdominal fat in the NEAUHLF and the Northeast Agricultural University F(2) (NEAU F(2)) resource population (Li ; Leng ). The purpose of the current study was to assess whether IGFBP2 is directly involved in lipid metabolism of chicken hepatocytes. Additional functions of IGFBP2 have recently been identified, many of which are IGF-independent, and involve intracellular and nuclear IGFBP2 activities. IGFBP2 has a classic nuclear localization signal sequence that is responsible for nuclear entry (Azar ), and enters the cell nucleus by a mechanism that involves its binding to importin-β (Azar ). IGFBP2 can bind integrins (Pereira ; Wang ; Holmes ) and activates PI3K/AKT (Mehrian-Shai ), NF-κB (Holmes ), and ERK signaling (Han ). IGFBP2 also potentiates nuclear EGFR/STAT3 signaling, thereby activating the expression of the corresponding downstream genes (Azar ; Chua ). In this study, the overexpression of IGFBP2 promoted the upregulated expression of the PPARG, IGF1, and IGF1R genes in chicken hepatocytes. While PPARGcross-talks with NF-κB signaling (Ide ; Yoshikawa ; Konstantinopoulos ), both IGF1 and IGF1R belong to the IGF1/AKT/STAT3 signaling axis (Yao ; Zhang ). Our results indicate that IGFBP2 influences the expression of PPARG, IGF1, and IGF1R, although it may not interact with them directly, and may indirectly interact through NF-κB, STAT3, and AKT signaling, which affects the expression of PPARG, IGF1, and IGF1R. The expression of LFABP is regulated by growth hormones and PPARα (Vida ; Graham ). In this study, the expression of LFABP was reduced by 24 h in the IGFBP2-overexpressing group. Therefore, IGFBP2 participates in the regulation of LFABP gene expression. The expression of APOAI is repressed by PPARGin HepG2 cells (Shavva ). In the present study, the expression of PPARG was upregulated by the overexpression of IGFBP2. However, the expression of APOAI decreased at 24h in the IGFBP2-overexpressing cells and in the control cells. This does not reflect the effect of IGFBP2 on the expression of the APOAI gene, but that the liposome transfection method affected the expression of the APOAI gene relative to that in the blank control group. At 48 and 72 h after transfection, the expression of both LFABP and APOAI was reduced in all three groups. A possible reason is that the secretory function of primary cultured hepatocytes is compromised in vitro, and the expression of secretion-related gene products is reduced (Sasaki ; Tachibana ; Bamji-Mirza ). The triglyceride content and glucose content were higher in the IGFBP2-overexpressing cells than in the control group. In a previous report, the methylation of hepatic IGFBP2 during infancy predicts the development of fatty liver later in life, and is linked to deterioration in glucose metabolism (Kammel ). In HEK293 cells, reduced IGFBP2 expression aggravates cell death during glucose deficiency, whereas the overexpression of IGFBP2 prolongs cell survival (Ord ). In the present study, IGFBP2 activated the expression of genes related to synthetic metabolic processes, such as PPARG, IGF1, and IGF1R. PPARGis the central coordinator of triglyceride synthesis, and the increased expression of PPARG-promotes triglyceride synthesis rate (Kershaw ). The IGF1 signal pathway has multiple effects on glucose metabolism. In rats, IGF1 reduces hepatic glucose production rate and increased peripheral glucose uptake (Simpson et al., 2004). In humans, IGF1 improves whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production (Rao et al., 2010). These findings indicate that IGFBP2 may participate in triglyceride synthesis and glucose absorption by regulating the expression of PPARG, IGF1, and IGF1R. In summary, overexpression of the IGFBP2 gene in chicken primary cultured hepatocytes increased the expression of the PPARG, IGF1, and IGF1R genes, and triglyceride synthesis rates. These results provide evidence that the expression of IGFBP2 in chicken hepatocytes contributes to the progression of triglyceride synthesis, thus implicating IGFBP2 as a gene potentially affecting fat deposition in chickens.
  44 in total

Review 1.  Structural and functional analysis of fatty acid-binding proteins.

Authors:  Judith Storch; Lindsay McDermott
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

Review 2.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

Authors:  R C Baxter
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-06       Impact factor: 4.310

3.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.

Authors:  Robert S Rosenson; H Bryan Brewer; M John Chapman; Sergio Fazio; M Mahmood Hussain; Anatol Kontush; Ronald M Krauss; James D Otvos; Alan T Remaley; Ernst J Schaefer
Journal:  Clin Chem       Date:  2011-01-25       Impact factor: 8.327

4.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Authors:  R Mehrian-Shai; C D Chen; T Shi; S Horvath; S F Nelson; J K V Reichardt; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression.

Authors:  Panagiotis A Konstantinopoulos; Gerasimos P Vandoros; Georgia Sotiropoulou-Bonikou; Athina Kominea; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2006-02-25       Impact factor: 2.571

6.  An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility.

Authors:  George K Wang; Limei Hu; Gregory N Fuller; Wei Zhang
Journal:  J Biol Chem       Date:  2006-03-28       Impact factor: 5.157

7.  Ascorbic acid supplementation to primary culture of chicken hepatocytes with non-serum medium.

Authors:  K Sasaki; Y Kitaguchi; T Fukuda; Y Aoyagi
Journal:  Int J Biochem Cell Biol       Date:  2000-09       Impact factor: 5.085

8.  Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.

Authors:  Helen L Simpson; Nicola C Jackson; Fariba Shojaee-Moradie; Richard H Jones; David L Russell-Jones; Peter H Sönksen; David B Dunger; A Margot Umpleby
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

9.  IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Authors:  C Y Chua; Y Liu; K J Granberg; L Hu; H Haapasalo; M J Annala; D E Cogdell; M Verploegen; L M Moore; G N Fuller; M Nykter; W K Cavenee; W Zhang
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.

Authors:  Tomohiro Ide; Hitoshi Shimano; Tomohiro Yoshikawa; Naoya Yahagi; Michiyo Amemiya-Kudo; Takashi Matsuzaka; Masanori Nakakuki; Shigeru Yatoh; Yoko Iizuka; Sachiko Tomita; Ken Ohashi; Akimitsu Takahashi; Hirohito Sone; Takanari Gotoda; Jun-ichi Osuga; Shun Ishibashi; Nobuhiro Yamada
Journal:  Mol Endocrinol       Date:  2003-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.